Infectious complications of chemotherapy in clinically aggressive mature B and T cell lymphomas

European Journal of Internal Medicine

Volumn 23, Issue 3, 2012, Pages 255-260

  Alonso, Juan José ^a,b   Cánovas, Araceli ^a   Barreiro, José Guillermo ^a   Aguirre, Ciriaco ^a,b  

^a HOSPITAL DE CRUCES   (Spain)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Chemotherapy; Infection; Lymphoma; Performance status

Indexed keywords

CIPROFLOXACIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; BACTEREMIA; CANCER COMBINATION CHEMOTHERAPY; FEBRILE NEUTROPENIA; FEMALE; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; OBSERVATIONAL STUDY; PNEUMONIA; PROSPECTIVE STUDY; PYREXIA IDIOPATHICA; RISK FACTOR; T CELL LYMPHOMA; TEACHING HOSPITAL; URINARY TRACT INFECTION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFECTION; LYMPHOMA, B-CELL; LYMPHOMA, T-CELL; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEUTROPENIA; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84858746699     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2011.11.018     Document Type: Article

References (40)

1. A. Jemal, R. Siegel, E. Ward, J. Hao, J. Xu, and T. Murray Cancer Statistic 2008 CA Cancer J Clin 58 2008 71 96
2. R.I. Fisher, E.R. Gaynor, S. Dahlberg, M.M. Oken, T.M. Grogan, and E.M. Mize Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma N Engl J Med 328 1993 1002 1006 (Pubitemid 23095683)
3. B. Coiffier, E. Lepage, J. Briere, R. Herbrecht, H.R. Tilly, and P. Morel CHOP chemotherapy plus Rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma N Engl J Med 346 2002 235 242 (Pubitemid 34438862)
4. G.H. Lyman, V.A. Morrison, D.C. Dale, J. Crawford, D.J. Delgado, and M. Fridman Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy Leuk Lymphoma 44 2003 2069 2076 (Pubitemid 37369646)
5. D.C. Dale, G.C. McCarter, J. Crawford, and G.H. Lyman Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials J NCCN 2 2003 440 1454
6. G.P. Bodey, M. Buckley, Y.S. Sathe, and E.J. Freireich Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia Ann Intern Med 64 1966 328 340
7. E.J. Bow Infection risk and cancer chemotherapy: the impact of the chemotherapeutic regimen in patients with lymphoma and solid tissue malignancies JAC 41 1998 S1 S5
8. L.W. Kwak, J. Halpern, R.A. Olshen, and S.J. Horning Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis J Clin Oncol 8 1990 963 977 (Pubitemid 20200184)
9. J. Crawford, H. Ozer, R. Stoller, D. Johnson, G. Lyman, and I. Tabbara Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer N Engl J Med 325 1991 164 170
10. J. Bohlius, M. Reiser, G. Schwarzer, and A. Engert Granulopoiesis- stimulating factors to prevent adverse effects in the treatment of malignant lymphoma Cochrane Database Syst Rev 2004 CD003189
11. N.M. Kuderer, D.C. Dale, J. Crawford, and G.H. Lyman Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review J Clin Oncol 25 2007 3158 3167 (Pubitemid 47218066)
12. American Society of Clinical Oncology Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines J Clin Oncol 12 1994 2471 2508
13. T.J. Smith, J. Khatcheressian, G.H. Lyman, H. Ozer, J.O. Armitage, and L. Balducci 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline J Clin Oncol 24 2006 3187 3205 (Pubitemid 46638957)
14. R. Aapro, D.A. Cameron, and M. Pettengell EORTC guidelines for the use of GCSF to reduce the incidence of chemotherapy induced febrile neutropenia in adult patients with lymphoma or solid tumors Eur J Cancer 42 2006 2433 2453 (Pubitemid 44442936)
15. G.H. Lyman, C.H. Lyman, and O. Agboola Risk models for predicting chemotherapy-induced neutropenia Oncologist 10 2005 427 437 (Pubitemid 40993570)
16. E. Anaissie, D. Kontoyiannis, S. O'Brien, H. Kantarjian, L. Robertson, and S. Lerner Infections in patients with chronic lymphocytic leukemia treated with fludarabine Ann Inter Med 129 1998 559 566 (Pubitemid 28460297)
17. S. Scott Identification of cancer patients at high risk of febrile neutropenia Am J Health Syst Pharm 59 2002 S16 S19
18. A.P. Rabinowitz, N.J. Weiner, B.S. Tronic, M. Fridman, R.F. Liberman, and D.J. Delgado Severe neutropenia in CHOP occurs most frequently in cycle 1: a predictive model Leuk Lymphoma 47 2006 853 858 (Pubitemid 43840640)
19. R. Pettengell, A. Bosly, T.D. Szucs, C. Jackisch, R.L. Paridaens, and M. Constenla Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU. Prospective Observational European Neutropenia Study Br J Haematol 144 2008 667 678
20. V.A. Morrison, K.R. Rai, B.L. Peterson, J.E. Kolitz, E. Laurence, and F.R. Appelbaum Impact of therapy with chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: intergroup study cancer and leukemia group B 9011 J Clin Oncol 19 2001 3611 3621 (Pubitemid 32791321)
21. M.L. Janssen-Heijnen, D.J. van Spronsen, and V.E. Lemmens A population-based study of severity of comorbidity among patients with non-Hodgkin's lymphoma: prognostic impact independent of International Prognostic Index Br J Haematol 129 2005 597 601
22. A.M. Tsimberidou, A. Younes, J. Romaguera, F.B. Hagemeister, M.A. Rodriguez, and L. Feng Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen Cancer 104 2005 345 353 (Pubitemid 40993262)
23. E. Velasco, R. Byington, C.A. Martins, M. Schirmer, L.M. Dias, and V.M. Gonçalves Comparative study of clinical characteristics of neutropenic and non-neutropenic adult cancer patients with bloodstream infections Eur J Clin Microbiol Infect Dis 25 2006 1 7 (Pubitemid 43207321)
24. J.G. Perkins, J.M. Flynn, R.S. Howard, and J.C. Byrd Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population Cancer 94 2002 2033 2039 (Pubitemid 34270057)
25. The International Non-Hodgkin's Lymphoma Prognostic Factors Project A predictive model for aggressive non-Hodgkin's lymphoma N Engl J Med 329 1993 987 994
26. W.T. Hughes, D. Armstrong, G.P. Bodey, A.E. Brown, J.E. Edwards, and R. Feld 1997 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America Clin Infect Dis 25 1997 551 573 (Pubitemid 127774275)
27. W.T. Hughes, D. Armstrong, G.P. Bodey, E.J. Bow, A.E. Brown, and T. Calandra 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer Clin Infect Dis 34 2002 730 751 (Pubitemid 34194843)
28. Cancer Therapy Evaluation Program.National Cancer Institute. The revised Common Toxicity Criteria.Version 2.0(CTEP website).Available from URL: http://ctep.info.nih.gov.
29. F.A. Pizzo, D. Arsmstrong, G. Bodey From the Immunocompromised Host Society The design, analysis and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient J Infect Dis 161 1990 397 401 (Pubitemid 20107934)
30. F. Cabanillas, M.A. Rodríguez, and F. Swan Jr. Recent trends in the management of lymphomas at M.D. Anderson Cancer Center Semin Oncol 17 1990 28 34
31. I.F. Khouri, J. Romaguera, H. Kantarjian, J.L. Palmer, W.C. Pugh, and M. Korbling Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma J Clin Oncol 16 1998 3803 3809 (Pubitemid 29001533)
32. J.D.C. Case, C.E. Desch, L.A. Kalman, R.R. Mena, L. Fridman, and B. Allen Community based trial of Rituximab-CHOP for intermediate or high grade Non-Hodgkin Lymphoma Clin Lymphoma Myeloma 7 2007 354 360
33. C.L. Bennet, J.A. Weeks, M.R. Sommerfield, and T.J. Smith Use of colony-stimulating factors: comparison of the 1994 and 1997 ASCO surveys regarding ASCO clinical practice guidelines. Health Services Research Committee of the ASCO J Clin Oncol 17 1999 3676 3681 (Pubitemid 29517939)
34. W. Kern, V. Winfried, A. Cometta, R. de Bock, J. Langenaeken, and M. Paesmans The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy N Engl J Med 341 1999 312 318 (Pubitemid 29350301)
35. G.H. Lyman, and D.J. Delgado Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma Cancer 98 2003 2402 2409 (Pubitemid 37466655)
36. M. Heuser, A. Ganser, and C. Bokemeyer American Society of Clinical Oncology. National Comprehensive Cancer Network. European Organization for Research and Treatment of Cancer. Use of colony-stimulating factors for chemotherapy-associated neutropenia: review of current guidelines Semin Hematol 44 2007 148 156
37. M.A. Sanz, J. Lopez, J.J. Lahuerta, M. Rovira, M. Batlle, and C. Pérez Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial JAC 50 2002 79 88 (Pubitemid 34785258)
38. M. Rubio, L. Palau, J.R. Vivas, E. del Potro, J. Diaz-Mediavilla, and A. Alvarez Predominance of gram-positive microorganisms as a cause of septicemia in patients with hematological malignancies Infect Control Hosp Epidemiol 15 1994 101 104
39. J. García-Suárez, I. Krsnik, E. Reyes, D. Miguel, N. Hernanz, and Barr-Alí Elderly hematological patients with chemotherapy-induced febrile neutropenia have similar rates of infection and outcome to younger adults: a prospective study of risk-adapted therapy Br J Haematol 120 2003 209 216 (Pubitemid 36194168)
40. L. Vidal, P. Mical, dor I. Ben, K. Soares-Weiser, and L. Leibovici Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients: a systematic review and meta-analysis of randomized trials JAC 54 2004 29 37 (Pubitemid 39028964)